Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01792310 : A Phase 1/2A Study of Minerval in Adult Patients With Advanced Solid Tumours
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria

- Males or females providing written, informed consent

- Histologically- or cytologically-confirmed advanced solid malignancy that is
refractory to standard-of-care treatment, or for which there is no standard therapy.
If this is glioma:Grade III / Grade IV malignant glioma recurring or progressing
after first or second line standard-of-care treatment and true progressive disease,
confirmed according to the RANO criteria 4.

- Life-expectancy of at least 12 weeks

- Eastern cooperative oncology group (ECOG) performance status of 0-2

- Safety laboratory tests and ECGs within specified limits.

- Using adequate contraception, where applicable

- Presence of lesions suitable for biopsy (mandatory for non-glioma patients enrolled
in the expanded safety cohort and highly desirable for non-glioma patients enrolled
in the dose escalation phase)

Exclusion Criteria

- Anti cancer therapy within 4 weeks (6 weeks for mitomycin and nitrosureas and 2 weeks
for palliative radiotherapy)

- NCI Common terminology criteria for adverse events (CTCAE) >Grade 1 toxicities from
prior chemotherapy or radiotherapy that could impact on safety outcome assessment

- Recent >Grade 1 intracranial or intratumoural haemorrhage either by CT or MRI scan.
Patients with resolving haemorrhage changes, punctuate haemorrhage or haemosiderin
may enter the study

- Significant or uncontrolled cardiovascular disease, unstable angina or myocardial
infarction within the preceding 6 months

- Known impairment of GI function that could alter the absorption of study drug

- History of uncontrolled hyperlipidemia and/or the need for concurrent lipid lowering
therapy

- Concurrent severe and/or uncontrolled other medical disease that could compromise
participation in the study

- Taking warfarin, phenytoin or sulphonylureas (glibenclamide, glimepiride, glipizide,
glyburide or nateglanide)

- Pregnant or breast feeding Other protocol specific criteria may apply
LinksPermanent Link to THIS page: http://virtualtrials.com/nct/display1trial.cfm?nct=NCT01792310      |      Link to official Clinicaltrials.gov listing
Locations
Barcelona,
Spain

Facility: Vall D'Hebron Institute of Oncology
Investigator: Dr Jordi Rodon
Contact:
Email not avaialable

Bilbao,
Spain

Facility: Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre
Investigator:
Contact: Dr Ricardo Fernandez Rodriguez
Email not avaialable

San Sebastián,
Spain

Facility: Onkologikoa
Investigator:
Contact: Dr Ander Urruticoechea Ribate
Email not avaialable

Newcastle, Newcastle upon Tyne
United Kingdom

Facility: Sir Bobby Robson Cancer Trials Research Centre, The Northern Centre for Cancer Care, Freeman Hospital
Investigator: Professor Ruth Plummer, BMBCh, MRCP, Cert Me
Contact:
Email not avaialable

Sutton, Surrey
United Kingdom

Facility: The Royal Marsden Hospital Drug Development Unit
Investigator: Professor Johann deBono, MB ChB FRCP MSc PhD
Contact:
Email not avaialable




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites